Advice
in the absence of a submission from the holder of the marketing authorisation:
fezolinetant (Veoza®) is not recommended for use within NHSScotland.
Indication under review: treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice228KB (PDF)
Medicine details
- Medicine name:
- fezolinetant (Veoza)
- SMC ID:
- SMC2702
- Indication:
Treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.
- Pharmaceutical company
- Astellas Pharma Ltd
- BNF chapter
- Obstetrics, gynaecology, and urinary-tract disorders
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 12 August 2024